Biotech
Top 2025 Biotech, MedTech, and Pharma Conferences You Can’t Miss
Overview: A look at the major biotech, medtech, and pharma conferences in 2025. Key Details: Dates, locations, and highlights from each event. Industry Impact: Why
Overview: A look at the major biotech, medtech, and pharma conferences in 2025. Key Details: Dates, locations, and highlights from each event. Industry Impact: Why
Quick Summary •FDA Clearance: LumiThera’s Valeda system becomes the first FDA-approved treatment for dry age-related macular degeneration (AMD). •Technology: Utilizes photobiomodulation (PBM) therapy to stimulate
Quick Summary •CMS Coverage: CMS has approved Medtronic’s renal denervation procedure for patients with resistant hypertension. •Innovation: This minimally invasive treatment targets kidney nerves to
Quick Summary •Market Reaction: Biotech stocks saw modest gains following Trump’s 2024 election victory, reflecting optimism about regulatory leniency and M&A activity. •Key Appointments: Speculation
Quick Summary •Trend: AI-generated prior art is reshaping biotech patent law, challenging traditional approaches to intellectual property protection. •Key Issues: Authenticity, enablement, public accessibility, and
Quick Summary •Setback: Neurogene reported an adverse event in its high-dose gene therapy trial for Rett syndrome, involving liver toxicity and immune responses. •Key Issue:
Quick Summary Issue: The emergence of AI-generated prior art is disrupting traditional patent law. Key Impacts: Challenges include authenticity, public accessibility, and erosion of blocking
Quick Summary Event: Neurogene’s stock fell 44% after reporting a severe adverse event in its high-dose gene therapy trial for Rett syndrome. Clinical Concern: The
Quick Summary Approval: The Centers for Medicare & Medicaid Services (CMS) now covers Medtronic’s renal denervation procedure for hypertension. Treatment: Renal denervation targets nerves in
Quick Summary FDA Approval: The FDA has granted clearance for LumiThera’s Valeda system, the first treatment approved for dry age-related macular degeneration (AMD). Technology: The